Diagnosis and Prognosis of Inflammatory Bowel Diseases

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 392

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gastroenterology, Dietetics and Internal Diseases, University of Medical Sciences Poznan, Przybyszewskiego 49, 60-355 Poznan, Poland
Interests: gastroenterology; human nutrition; internal diseases; inflammatory bowel diseases

Special Issue Information

Dear Colleagues,

Inflammatory Bowel Diseases (IBD) is a non-specific inflammatory disease of the intestine with unknown etiology, including Crohn's Disease (CD) and Ulcerative Colitis (UC). Both of these diseases involve intestinal inflammation and the disruption of the mucosal barrier, leading to symptoms such as diarrhea, abdominal pain, and bloody stools.

The most accurate method for diagnosing IBD is colonoscopy, which can help in observing the inflammation and the lesion site of the intestinal mucosa. In addition, auxiliary examinations such as blood tests, X-rays, and CTs can also help diagnose the disease. During the diagnosis process, doctors will comprehensively consider the patient's symptoms, signs, and examination results to make an accurate diagnosis.

Although the pathogenesis of IBD is still not fully understood, studies have identified some possible risk factors, such as genetic factors, immune factors, environmental factors, etc. In the future, we need to further deepen our understanding of the pathogenesis of IBD, providing more effective means for the early diagnosis and prognosis of the disease.

Dr. Liliana Łykowska-Szuber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • tuberculosis
  • acute pancreatitis
  • chronic pancreatitis
  • celiac disease
  • biliary disease
  • gall bladder diseases
  • pancreatic cancer
  • colon cancer
  • diverticulitis
  • gastrointestinal infections
  • esophageal cancer
  • Barrett esophagus

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

17 pages, 1770 KiB  
Systematic Review
Unraveling the Interplay of KRAS, NRAS, BRAF, and Micro-Satellite Instability in Non-Metastatic Colon Cancer: A Systematic Review
by Elena Orlandi, Mario Giuffrida, Serena Trubini, Enrico Luzietti, Massimo Ambroggi, Elisa Anselmi, Patrizio Capelli and Andrea Romboli
Diagnostics 2024, 14(10), 1001; https://doi.org/10.3390/diagnostics14101001 (registering DOI) - 12 May 2024
Viewed by 247
Abstract
Microsatellite Instability (MSI-H) occurs in approximately 15% of non-metastatic colon cancers, influencing patient outcomes positively compared to microsatellite stable (MSS) cancers. This systematic review focuses on the prognostic significance of KRAS, NRAS, and BRAF mutations within MSI-H colon cancer. Through comprehensive searches in [...] Read more.
Microsatellite Instability (MSI-H) occurs in approximately 15% of non-metastatic colon cancers, influencing patient outcomes positively compared to microsatellite stable (MSS) cancers. This systematic review focuses on the prognostic significance of KRAS, NRAS, and BRAF mutations within MSI-H colon cancer. Through comprehensive searches in databases like MEDLINE, EMBASE, and others until 1 January 2024, we selected 8 pertinent studies from an initial pool of 1918. These studies, encompassing nine trials and five observational studies involving 13,273 patients, provided insights into disease-free survival (DFS), survival after recurrence, and overall survival. The pooled data suggest that while KRAS and BRAF mutations typically predict poorer outcomes in MSS colorectal cancer, their impact is less pronounced in MSI contexts, with implications varying across different stages of cancer and treatment responses. In particular, adverse effects of these mutations manifest significantly upon recurrence rather than affecting immediate DFS. Our findings confirm the complex interplay between genetic mutations and MSI status, emphasizing the nuanced role of MSI in modifying the prognostic implications of KRAS, NRAS, and BRAF mutations in colon cancer. This review underscores the importance of considering MSI alongside mutational status in the clinical decision-making process, aiming to tailor therapeutic strategies more effectively for colon cancer patients. Full article
(This article belongs to the Special Issue Diagnosis and Prognosis of Inflammatory Bowel Diseases)
Show Figures

Figure 1

Back to TopTop